Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Neurocrine Biosciences (NBIX)

Neurocrine raises 2026 INGREZZA sales guidance; Q2 revenue up 39% to $959 million

Positive Impact 4 of 5 earnings Written later

Neurocrine Biosciences reported second-quarter 2026 revenue of $959 million, up 39% from $688 million a year earlier, with GAAP diluted earnings per share of $1.39 versus $1.06. The company raised its full-year 2026 INGREZZA net sales guidance to $2.825 billion to $2.875 billion from $2.7 billion to $2.8 billion, and it completed its Soleno Therapeutics acquisition in May 2026.

Key points

  • Total revenue was $959 million in Q2 2026 versus $688 million in Q2 2025.
  • GAAP net income was $144 million, or $1.39 per diluted share, versus $108 million, or $1.06, a year earlier.
  • INGREZZA full-year 2026 net product sales guidance was raised to $2.825 billion to $2.875 billion from $2.7 billion to $2.8 billion.
  • VYKAT XR net product sales were $54 million from May 18, 2026, the Soleno acquisition closing date.

The filing

CompanyNeurocrine Biosciences (NBIX)
Form8-K, current report
Filed with the SECJul 30, 2026, 4:02 PM ET
Accession number0000914475-26-000035

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:11 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 30, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.